Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

297
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
297
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

463
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
463
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

657
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
657
Time Course of Drug Effect01:14

Time Course of Drug Effect

2.6K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.6K
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

1.0K
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
1.0K
Elimination Kinetics: First-Order and Zero-Order01:05

Elimination Kinetics: First-Order and Zero-Order

2.6K
Eliminating drugs from the body is a vital process that occurs through excretion or metabolism. Understanding the kinetics of drug elimination is crucial for drug development, dosage determination, and optimizing patient outcomes.
Drug clearance depends on the rate of drug elimination and its plasma concentration. Another important parameter is a drug's half-life, which is the time required for its concentration to decrease by half. In most cases, drug clearance follows first-order...
2.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Toward the Future: A Race-Agnostic, Bayesian Approach to Defining Glomerular Filtration for Personalized Drug Dosing.

Clinical pharmacology and therapeutics·2026
Same author

Deep learning-powered quantification of endocrine cells and CD3<sup>+</sup> T cells in the natural history of type 1 diabetes.

Diabetologia·2026
Same author

Autosomal Dominant Tubulointerstitial Kidney Disease Clinical Trial Simulator: Case Reports of Model-Informed Drug Development.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Bayesian Dosing Simulator (BDS): A Pharmacokinetic Modeling Tool for Optimized Antibiotic Therapy.

Pharmacotherapy·2026
Same author

Identifying optimal combination regimens for therapy of Mycobacterium tuberculosis with an algorithmic approach: prospective predictions and validations.

PloS one·2026
Same author

Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumonia.

Antimicrobial agents and chemotherapy·2025
Same journal

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

A Narrative Review of Artificial Intelligence for Drug Repurposing: Lessons From COVID-19 and Oncology (2020-2025).

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Butorphanol Pharmacokinetics Across Species: Meta-Analysis Integrating Allometric Scaling and Minimal Physiologically Based Pharmacokinetic Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Accelerating Subcutaneous Drug Development: A Mechanistic Absorption Model for the Open Systems Pharmacology Framework.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Automated Pharmacometric Model Development by Leveraging Low-Dimensional Neural ODEs and LASSO Regression.

CPT: pharmacometrics & systems pharmacology·2026
查看所有相关文章

相关实验视频

Updated: Jan 9, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

672

分析药理动力学计数数据,这些数据迅速减少到零.

Walter M Yamada1, Alan Schumitzky1, Alona Kryshchenko2

  • 1Children's Hospital Los Angeles, Los Angeles, California, USA.

CPT: pharmacometrics & systems pharmacology
|December 4, 2025
PubMed
概括
此摘要是机器生成的。

药物治疗后感染反弹的准确建模需要仔细考虑计数数据分布. 假设Poisson对低数量和高数量的正常性最好预测治疗疗效和缺乏反弹.

关键词:
这就是Pmetrics.鱼类分布 鱼类分布殖民地形成单位.数计数据 数计数据 数计数据 数计数据非参数的最大概率.

更多相关视频

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.2K

相关实验视频

Last Updated: Jan 9, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

672
High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.2K

科学领域:

  • 药理动力学/药理动力学 (PK/PD) 是一个
  • 统计建模 统计建模
  • 传染病的动态传染病的动态.

背景情况:

  • 准确估计感染反弹对于评估药物疗效至关重要.
  • 抗微生物研究中的计数数据通常表现为高至零的模式.
  • 现有的统计方法可能无法优化处理此数据特征.

研究的目的:

  • 开发和评估药物比较研究中计数数据的最大概率分析框架.
  • 为了比较不同的概率分布假设 (Poisson, Normal) 用于模拟感染反弹.
  • 确定最佳的统计方法来预测治疗结果.

主要方法:

  • 模拟殖民地形成单元 (CFU) 配置文件使用Emax抑制PK-PD模型.
  • 基于CFU计数的四种不同的概率分布假设,优化了模型参数.
  • 评估感染反弹的预测准确性 (CFU ≥10在治疗后24小时).

主要成果:

  • 假设低CFU计数 (<128) 的Poisson分布和较高CFU计数的正常分布的策略提供了反弹百分比的最佳预测.
  • 在低计数时使用波桑分布的建模准确地反映了没有反弹的真实比例.
  • 对于计数≥128的正常性假设是合理的,而对数据的审查导致了偏见的模型.

结论:

  • 建议将波桑分布和正常分布相结合的混合方法用于分析降至零的计数数据.
  • 这一框架改善了感染反弹和治疗疗效的预测.
  • 适当的统计建模对于对抗微生物研究结果进行可靠的解释至关重要.